ACM
NDRA icon

AIGH Capital Management’s ENDRA Life Sciences NDRA Stock Holding History

AIGH Capital Management’s Portfolio NDRA Stock Details NDRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-37
Closed -$975K – 59
2020
Q4 		$975K Buy
+37
New +$988K 0.4% 40

Other funds holding NDRA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FHA
Flagship Harbor Advisors Boston, Massachusetts $2.27B AUM 18.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
5L
55I LLC Boston, Massachusetts $3.58B AUM 17.97% 1-Year Est. Return
KJHP
K.J. Harrison & Partners Toronto, Ontario, Canada $608M AUM 45.31% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

AIGH Capital Management's NDRA Position: Q1 2021 in Review

AIGH Capital Management sold out of ENDRA Life Sciences (NDRA) in Q1 2021, closing a stake of 37 shares — an estimated $975K sold.

AIGH Capital Management first reported a position in NDRA in Q4 2020 and held it in 1 quarter. The position peaked at $975K in Q4 2020. 12 funds tracked by Wall St. Rank hold NDRA as of Q1 2021.

  • AIGH Capital Management reported no remaining ENDRA Life Sciences position as of Q1 2021 after selling out during the quarter.
  • AIGH Capital Management sold 37 ENDRA Life Sciences shares in Q1 2021, an estimated $975K.
  • AIGH Capital Management first reported a position in ENDRA Life Sciences in Q4 2020 and held it in 1 quarter.
  • AIGH Capital Management's ENDRA Life Sciences position peaked at $975K in Q4 2020.
  • 12 funds tracked by Wall St. Rank held ENDRA Life Sciences as of Q1 2021.

Based on AIGH Capital Management's 13F filing for Q1 2021, filed 13 May 2021.